You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(00874.HK)收到兩個藥品補充申請批件
格隆匯 04-08 18:24

格隆匯4月8日丨白雲山(00874.HK)發佈公告,公司獲悉,公司分公司廣州白雲山醫藥集團股份有限公司白雲山製藥總廠和全資子公司廣州白雲山中一藥業有限公司於近日收到廣東省藥品監督管理局核准簽發的兩個品種(羧甲司坦口服溶液及姜顆粒)的《藥品補充申請批件》。

羧甲司坦口服溶液適用於治療慢性支氣管炎、支氣管哮喘等疾病引起的痰液粘稠、咳痰困難患者。在國家藥品監督管理局網站查詢,羧甲司坦口服溶液共有13個批准文號。根據米內網數據顯示,2018年羧甲司坦口服溶液在中國公立醫院和城市零售藥店的銷售額分別為人民幣17,766萬元和人民幣677萬元。除此之外,公司無法從公開渠道獲悉其他生產企業此藥品的生產或銷售數據。2019年度白雲山製藥總廠該規格藥品的銷售收入為人民幣1,222萬元,約佔公司2019年度營業收入的0.02%。

姜顆粒的功能主治為暖脾胃,散風寒。用於胃寒,心腹冷痛,脹滿或外感風寒。在國家藥品監督管理局網站查詢,姜顆粒共有4個批准文號。根據米內網數據顯示,浙江愛諾生物藥業股份有限公司2018年在中國城市零售藥店的銷售額為人民幣109萬元。除此之外,公司無法從公開渠道獲悉其他生產企業此藥品的生產或銷售數據。中一藥業該藥品暫未投入生產和銷售。

公司稱,白雲山製藥總廠獲得廣東省藥品監督管理局批件,延長了該藥品有效期,有利於提高藥品的市場競爭力;中一藥業獲得廣東省藥品監督管理局批件,該藥品獲批上市生產,有利於豐富中一藥業產品結構。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account